The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol (Pharmaceutical Research DOI: 10.1007/s11095-008-9677-1);The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol

Pharmaceutical Research

Volumn 25, Issue 11, 2008, Pages 2593-2600

  Das, Surajit ^a   Lin, Hai Shu ^a   Ho, Paul C ^a   Ng, Ka Yun ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Aqueous solubility; Bioavailability; Dose manipulation; Pharmacokinetics; Resveratrol

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; CARBOXYMETHYLCELLULOSE; RESVERATROL;

AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUSPENSION;

EID: 53849145999     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9701-5     Document Type: Erratum

References (32)

1. J. A. Baur D.A. Sinclair 2006 Therapeutic potential of resveratrol: the in vivo evidence Nat. Rev. Drug. Discov. 5 493 506
2. J. A. Baur K. J. Pearson N. L. Price H. A. Jamieson C. Lerin A. Kalra V. V. Prabhu J. S. Allard G. Lopez-Lluch K. Lewis P. J. Pistell S. Poosala K. G. Becker O. Boss D. Gwinn M. Wang S. Ramaswamy K. W. Fishbein R. G. Spencer E. G. Lakatta D. Le Couteur R. J. Shaw P. Navas P. Puigserver D. K. Ingram R. de Cabo D. A. Sinclair 2006 Resveratrol improves health and survival of mice on a high-calorie diet Nature 444 337 342
3. M. Jang L. Cai G. O. Udeani K. V. Slowing C. F. Thomas C. W. Beecher H. H. Fong N. R. Farnsworth A. D. Kinghorn R. G. Mehta R. C. Moon J. M. Pezzuto 1997 Cancer chemopreventive activity of resveratrol, a natural product derived from grapes Science 275 218 220
4. ClinicalTrial.gov. A service of the U.S. National Institutes of Health. http://www.clinicaltrial.gov/ct2/results?term=resveratrol.
5. D. Delmas A. Lancon D. Colin B. Jannin N. Latruffe 2006 Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer Curr. Drug Targets 7 423 442
6. D. M. Goldberg J. Yan G. J. Soleas 2003 Absorption of three wine-related polyphenols in three different matrices by healthy subjects Clin. Biochem. 36 79 87
7. T. Walle F. Hsieh M. H. DeLegge J. E. Oatis Jr. U. K. Walle 2004 High absorption but very low bioavailability of oral resveratrol in humans Drug Metab. Dispos. 32 1377 1382
8. D. J. Boocock G. E. Faust K. R. Patel A. M. Schinas V. A. Brown M. P. Ducharme T. D. Booth J. A. Crowell M. Perloff A. J. Gescher W. P. Steward D. E. Brenner 2007 Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent Cancer Epidemiol. Biomarkers Prev. 16 1246 1252
9. S. Hurst C.M. Loi J. Brodfuehrer A. El-Kattan 2007 Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans Expert Opin. Drug Metab. Toxicol. 3 469 489
10. O. H. Chan B. H. Stewart 1996 Physicochemical and drug-delivery considerations for oral drug bioavailability Drug Discov. Today 1 461 473 doi:10.1016/1359-6446(96)10039-8
11. M. I. Kaldas U. K. Walle T. Walle 2003 Resveratrol transport and metabolism by human intestinal Caco-2 cells J. Pharm. Pharmacol. 55 307 312
12. A. Maier-Salamon B. Hagenauer M. Wirth F. Gabor T. Szekeres W. Jager 2006 Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites Pharm. Res. 23 2107 2115
13. V. Bertacche N. Lorenzi D. Nava E. Pini C. Sinico 2006 Host-guest interaction study of resveratrol with natural and modified cyclodextrins J. Incl. Phenom. Macrocycl. Chem. 55 279 287 doi:10.1007/s10847-006-9047-8
14. J. F. Marier P. Vachon A. Gritsas J. Zhang J. P. Moreau M. P. Ducharme 2002 Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model J. Pharmacol. Exp. Ther. 302 369 373
15. C. Yu Y. G. Shin A. Chow Y. Li J. W. Kosmeder Y. S. Lee W. H. Hirschelman J. M. Pezzuto R. G. Mehta R. B. van Breemen 2002 Human, rat, and mouse metabolism of resveratrol Pharm. Res. 19 1907 1914
16. A. J. Gescher W. P. Steward 2003 Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum Cancer Epidemiol. Biomarkers Prev. 12 953 957
17. M. E. Davis M. E. Brewster 2004 Cyclodextrin-based pharmaceutics: past, present and future Nat. Rev. Drug Discov. 3 1023 1035
18. A. Katsagonis J. Atta-Politou M. A. Koupparis 2005 HPLC method with UV detection for the determination of trans-resveratrol in plasma J. Liq. Chromatogr. Relat. Technol. 28 1393 1405 doi:10.1081/JLC-200054884
19. H. S. Lin C. S. Chean Y. Y. Ng S. Y. Chan P. C. Ho 2000 2-hydroxypropyl-beta-cyclodextrin increases aqueous solubility and photostability of all-trans-retinoic acid J. Clin. Pharm. Ther. 25 265 269
20. T. Higuchi K. A. Connors 1965 Phase-solubility techniques Advan. Anal. Chem. Instr. 4 117 212
21. H. S. Lin S. Y. Chan K. S. Low M. L. Shoon P. C. Ho 2000 Kinetic study of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of all-trans-retinoic acid in Sprague-Dawley rats after oral or intravenous administration J. Pharm. Sci. 89 260 267
22. H. S. Lin W. W. Leong J. A. Yang P. Lee S. Y. Chan P. C. Ho 2007 Biopharmaceutics of 13-cis-retinoic acid (isotretinoin) formulated with modified beta-cyclodextrins Int. J. Pharm. 341 238 245
23. H. S. Lin A. B. Barua J. A. Olson K. S. Low S. Y. Chan M. L. Shoon P. C. Ho 2001 Pharmacokinetic study of all-trans-retinoyl-beta-d-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s) J. Pharm. Sci. 90 2023 2031
24. K. Uekama M. Otagiri 1987 Cyclodextrins in drug carrier systems Crit. Rev. Ther. Drug Carr. Syst. 3 1 40
25. C. F. Hung Y. K. Lin Z. R. Huang J. Y. Fang 2008 Delivery of resveratrol, a red wine polyphenol, from solutions and hydrogels via the skin Biol. Pharm. Bull. 31 955 962
26. G. Piel B. Evrard T. Van Hees L. Delattre 1999 Comparison of the IV pharmacokinetics in sheep of miconazole-cyclodextrin solutions and a micellar solution Int. J. Pharm. 180 41 45
27. V. J. Stella V. M. Rao E. A. Zannou V. V. Zia 1999 Mechanisms of drug release from cyclodextrin complexes Adv. Drug Deliv. Rev. 36 3 16
28. Z. Lu Y. Zhang H. Liu J. Yuan Z. Zheng G. Zou 2007 Transport of a cancer chemopreventive polyphenol, resveratrol: interaction with serum albumin and hemoglobin J. Fluoresc. 17 580 587
29. O. H. Chanand B. H. Stewart 1996 Physicochemical and drug delivery considerations for oral drug bioavailability Drug Discov. Today 1 461 473 doi:10.1016/1359-6446(96)10039-8
30. C. De Santi A. Pietrabissa R. Spisni F. Mosca G. M. Pacifici 2000 Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum Xenobiotica 30 609 617
31. W. Andlauer J. Kolb K. Siebert P. Furst 2000 Assessment of resveratrol bioavailability in the perfused small intestine of the rat Drugs Exp. Clin. Res. 26 47 55
32. G. Kuhnle J. P. Spencer G. Chowrimootoo H. Schroeter E. S. Debnam S. K. Srai C. Rice-Evans U. Hahn 2000 Resveratrol is absorbed in the small intestine as resveratrol glucuronide Biochem. Biophys. Res. Commun. 272 212 217